Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

This study has been completed.

Study NCT00132002 Information provided by California Cancer Consortium

First Received: August 16, 2005 Last Updated: October 11, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	January 2008
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Publications:

Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Gandara DR, Aparicio A, Somlo G, Wong C. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008 Nov 1;14(21):7138-42.

Luu TH, Leong L, Morgan R, et al.: Vorinostat (suberoylanilide hydroxamic acid) as salvage therapy in metastatic breast cancer (MBC): a California Cancer Consortium phase II study. [Abstract] J Clin Oncol 25 (Suppl 18): A-11502, 2007.